Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1045
Abstract: In this open‐label, single‐dose, parallel‐group study, we compared the pharmacokinetic profile and safety of lobeglitazone, a thiazolidinedione acting as an agonist for peroxisome proliferator‐activated receptors, in patients with hepatic impairment (HI) and healthy matched controls… read more here.
Keywords: profile safety; safety lobeglitazone; lobeglitazone; pharmacokinetic profile ... See more keywords